Novartis names once-yearly zoledronic acid Aclasta
Aclasta will be the trade name for Novartis' once-yearly I.V. infusion formulation of zoledronic acid for treatment of Paget's disease. The priority review date on the Aclasta NDA is in March, the company said. Novartis anticipates a 2007 filing of Aclasta in treatment of osteoporosis (1"The Pink Sheet" Nov. 24, 2003, p. 29). Novartis also markets zoledronic acid under the trade name Zometa for treatment of prostate cancer...
You may also be interested in...
Further study of jaw osteonecrosis risk may differentiate Novartis' bisphosphonates Zometa and Aredia, FDA Division of Oncology Drug Products Director Richard Pazdur suggested
Novartis' clinical R&D portfolio has grown 44% over the last four years, with new molecular entities representing about half the drugs in development, Global Pharma Development Head Joerg Reinhardt, PhD, said Nov. 19 during Novartis' R&D day in New York
The appointment of Belén Garijo as CEO of the German major from May next year is a small but significant step on the road to addressing gender inequality at the very top level of management in the world of big pharma.